Skip to content
Stop using now Drug recall · FDA · Published June 27, 2012

Hospira Paclitaxel Recall: Glass Particles in Vials

Hospira recalls Paclitaxel Injection vials due to visible glass particles embedded in the neck. Check lot numbers for potential dislodgement into solution.

🇺🇸 FDA recall #D-1682-2012DrugHospira ›
Take action

Contact the company

Recalling firmHospira Inc.275 N Field Dr · Lake Forest, IL 60045-2579
✎ GovInfoNow plain-language explainer

Hospira Inc. is recalling specific lots of Paclitaxel Injection, 6 mg/mL, 50 mL Single Dose Vials because visible particles are embedded in the glass at the neck of the vial. These particles may become dislodged into the solution, posing a risk if injected. The recall covers 131,264 vials distributed nationwide and internationally. Read more at govinfonow.com/recall/48658-hospira-inc-recalls-paclitaxel-injection-6-mg-ml-50-ml.

Source Summary by GovInfoNow · govinfonow.com/recall/48658-hospira-inc-recalls-paclitaxel-injection-6-mg-ml-50-ml · Updated October 13, 2026 · FDA enforcement record: FDA #D-1682-2012

Cite this page

“Hospira Paclitaxel Recall: Glass Particles in Vials.” GovInfoNow, updated October 13, 2026. https://govinfonow.com/recall/48658-hospira-inc-recalls-paclitaxel-injection-6-mg-ml-50-ml. Based on FDA recall #D-1682-2012 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1682-2012%22&limit=1).

The FDA announced on June 27, 2012, that Hospira Inc. is recalling Paclitaxel Injection vials due to visible particles embedded in the glass neck of the vial. The agency said the particles may become dislodged into the solution.

How to tell if you have it

  • Brand: Hospira
  • Product: Paclitaxel Injection, 6 mg/mL, 50 mL Single Dose Vial
  • NDC: 61703-342-50
  • Lot numbers: Y096865AA (exp AUG 2013), Y106865AA (exp AUG 2013), Y116865AA (exp AUG 2013), Y126865AA (exp SEP 2013), Y136865AA (exp SEP 2013), Y146865AA (exp SEP 2013), Y156865AA (exp OCT 2013), Y166865AA (exp NOV 2013), Y176865AA (exp NOV 2013), and Y186865AA (exp DEC 2013)
  • Quantity: 131,264 vials
  • Distribution: Nationwide, including Puerto Rico and Guam; internationally to Australia, Belgium, Canada, France, Germany, Korea, Malaysia, New Zealand, Norway, Pakistan, Philippines, Portugal, Singapore, Sweden, Thailand and Vietnam

The hazard

The affected lots of Carboplatin Injection, Cytarabine Injection, Methotrexate Injection, USP, and Paclitaxel Injection are being recalled due to visible particles embedded in the glass located at the neck of the vial. There may be the potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.

Context

GovInfoNow's records show Hospira Inc. has 108 other recalls on record since 2012-04-05. Other recent recalls of similar products include American Regent Papaverine HCl Injection Recall (2026-07-24), Sun Pharmaceutical DOXOrubin Liposome Injection Recall (2026-05-12) and American Regent Epinephrine Injection Recall (2026-08-11).

How to tell if you have this one

Check for Paclitaxel Injection, 6 mg/mL, 50 mL Single Dose Vials manufactured by Hospira Inc. Look for NDC 61703-342-50 and the following lot numbers: Y096865AA, Y106865AA, Y116865AA, Y126865AA, Y136865AA, Y146865AA, Y156865AA, Y166865AA, Y176865AA, and Y186865AA.

  • Brand
    Hospira
  • Category
    Drug
FDA recall event · 4 products

All 4 products in this recall

FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.

  • Classification
    Class II
  • Status
    Terminated
  • Distribution
    Nationwide, including Puerto Rico and Guam. Product was also distributed internationally to Australia, Belgium, Canada, France, Germany, Korea, Malaysia, New Zealand, Norway, Pakistan, Philippines, Portugal, Singapore, Sweden, Thailand and Vietnam
Recall numberProduct, codes & lotsQuantityNDC
D-1679-2012Carboplatin Injection, 10 mg/mL, 45 mL Multi-Dose Vial, Rx only, antineoplastic/cytotoxic agent; Manufactured for Hospira, Inc., Lake Forest, IL 60045, Product of Australia, NDC 61703-339-50 (Hospira label), NDC 61703-360-50 (Novoplus label); lot numbers Y061711AA, exp FEB 2013 and Y061711AB, exp FEB 2013 rest of world lots being recalled: list M1685A001, lots numbers Y151686AB, exp MAY 2013 and Y131686AA, exp MAR 2013; list M1723A001, lot number Y121686AF, exp SEP 2013; list M1686ADE1, lot numbers Y121686AA, exp SEP 2013 and Y151686AC, exp NOV 2013; list M1686AFR1, lot numbers Y121686AG, exp SEP 2013 and Y131686AB, exp SEP 2013; list M1714A001, lot number Y121686AC, exp SEP 2013; list M1686ANO3, lot number Y121686AE, exp SEP 2013; list M1686ASE2, lot number Y121686AB, exp SEP 201330,582 vials61703-339-18, 61703-339-22, 61703-339-50, 61703-339-56, 61703-360-50
D-1680-2012Cytarabine Injection, 20 mg/mL, 50 mL Single Dose Vial, Rx only, antineoplastic/cytotoxic agent; Manufactured for Hospira, Inc., Lake Forest, IL 60045, Product of Australia; NDC 61703-303-46; lot numbers Y131994AA, exp AUG 2013; Y141994AA, exp SEP 2013; Y151994AA, exp SEP 2013; Y161994AA, exp NOV 2013; Y171994AA, exp NOV 2013 and Y181994AA, exp NOV 2013210 vials61703-303-46
D-1681-2012Methotrexate Injection, USP, 25 mg/mL, 40 mL Single Dose Vial, Rx only, antineoplastic/cytotoxic agent; Manufactured for Hospira, Inc., Lake Forest, IL 60045, Product of Australia; NDC 61703-408-41; lot number Y064457AA, exp OCT 2013 Rest of world lot numbers: list M4457A001, lot number Y054457AB, exp SEP 201334,572 vials61703-350-37, 61703-350-38, 61703-408-41
D-1682-2012Paclitaxel Injection, 6 mg/mL, 50 mL Single Dose Vial, Rx only, antineoplastic/cytotoxic agent; Manufactured for Hospira, Inc., Lake Forest, IL 60045, Product of Australia; N DC 61703-342-50; lot numbers Y096865AA, exp AUG 2013; Y106865AA, exp AUG 2013; Y116865AA, exp AUG 2013; Y126865AA, exp SEP 2013; Y136865AA, exp SEP 2013; Y146865AA, exp SEP 2013; Y156865AA, exp OCT 2013; Y166865AA, exp NOV 2013; Y176865AA, exp NOV 2013; and Y186865AA, exp DEC 2013131,264 vials61703-342-09, 61703-342-22, 61703-342-50, 61703-015-04
Based on the official FDA remedy

What to do — step by step

  1. Inspect Vials

    Check your inventory for Paclitaxel Injection vials with NDC 61703-342-50 and the specified lot numbers (Y096865AA through Y186865AA).

  2. Stop Use Immediately

    Do not use any vials matching the recalled lot numbers due to the risk of glass particles entering the solution.

Where it went and when

Where it was distributed

Distributed nationwide, and outside the U.S.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFLPuerto Rico: yesPR

FDA distribution: “Nationwide, including Puerto Rico and Guam. Product was also distributed internationally to Australia, Belgium, Canada, France, Germany, Korea, Malaysia, New Zealand, Norway, Pakistan, Philippines, Portugal, Singapore, Sweden, Thailand and…” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide, and outside the U.S.

Recall timeline

FDA terminated this recall 4.5 years after the firm started it.

1. Firm started the recall: Jun 27, 201212. FDA classified it Class II: Sep 19, 201223. Published in FDA’s Enforcement Report: Sep 26, 201234. FDA terminated the recall: Dec 15, 2016420122016
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

✎ GovInfoNow

Questions people ask

Where was this product distributed?

The product was distributed nationwide (including Puerto Rico and Guam) and internationally to countries such as Australia, Belgium, Canada, France, Germany, Korea, Malaysia, New Zealand, Norway, Pakistan, Philippines, Portugal, Singapore, Sweden, Thailand, and Vietnam.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-1682-2012 (June 27, 2012) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1682-2012 to see it in context.
  • Plain-language summary written by qwen3.6:35b-a3b on October 13, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA